| Title: |
CGRP-monoclonal antibodies and SARS-CoV-2 vaccination. |
| Authors: |
Schiano di Cola, Francesca1 (AUTHOR) francescaschiano@hotmail.it, Caratozzolo, Salvatore1 (AUTHOR), Liberini, Paolo1 (AUTHOR), Padovani, Alessandro1 (AUTHOR), Rao, Renata1 (AUTHOR) |
| Source: |
Journal of Neurology. Jun2022, Vol. 269 Issue 6, p2848-2849. 2p. |
| Subject Terms: |
*SARS-CoV-2 |
| Abstract: |
Out of 105 patients, 32 underwent COVID-19 vaccinations while on treatment with CGRP-mAbs (8 patients on erenumab 70 mg/4 weeks, 12 on erenumab 140 mg/4 weeks, 8 on galcanezumab, and 2 on fremanezumab). All patients who received the Astra-Zeneca/Vaxzevria vaccine only received the first dose, whereas all others received the full two vaccine administrations. In particular, five patients waited, on average, less than 5 days between CGRP-mAbs administration and COVID-19 vaccination. [Extracted from the article] |
|
Copyright of Journal of Neurology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
